Clinical Trial Update: Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating neoadjuvant Iparomlimab and Tuvonralimab for resectable hepatocellular carcinoma at high risk of recurrence; the study is not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Tongji Hospital | Conditions: Resectable Hepatocellular Carcinoma With High Risk of Recurrence | Phase 2 | Status: NOT_YET_RECRUITING